cardiac hypertrophy, cardiac interstitial fibrosis, cardiovascular system phenotype, decreased cardiac muscle contractility, decreased colon length, decreased pulmonary artery pressure, decreased susceptibility to Coronaviridae infection, decreased ventricle muscle contractility, dilated heart left ventricle, dilated heart ventricle, heart inflammation, increased NAD(P)H oxidase activity, increased angiotensin I-converting enzyme activity, increased angiotensin II level, increased circulating angiotensin II level, increased circulating interferon-gamma level, increased circulating interleukin-9 level, increased heart weight, increased incidence of corneal inflammation, increased left ventricle diastolic pressure, increased lung elastance, increased lung weight, increased neutrophil cell number, increased pulmonary respiratory rate, increased sensitivity to induced morbidity/mortality, increased susceptibility to Coronaviridae infection, increased susceptibility to Orthomyxoviridae infection, increased susceptibility to Orthomyxoviridae infection induced morbidity/mortality, increased susceptibility to bacterial infection induced morbidity/mortality, increased susceptibility to induced colitis, increased susceptibility to injury, increased susceptibility to pulmonary hyaline membrane formation, increased susceptibility to weight loss, increased systemic arterial systolic blood pressure, increased vascular permeability, lung hemorrhage, oxidative stress, pulmonary vascular congestion, thick pulmonary interalveolar septum, thin ventricular wall, yellow coat color